← Leaderboards
Margrit E Carlson
University Of California Los Angeles
$345,079
Attributed
$345,079
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $126.4K · FY2005–07$200K$150K$100K$50K$0
'05
'06
'07
Funding mix
By agency
NIH$345,079 · 6
By mechanism
M01$345,079 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Judith S. Currier$525,401,794
- Yvonne J Bryson$45,728,199
- Chelsea M Kidwell$11,981,128
- Debika Bhattacharya$3,936,355
- Steven Grant Deeks$52,964,444
Others in their field
Top investigators on “Microorganism Disease Chemotherapy”
- Bruce D Walker · Massachusetts General Hospital$6,506,739
- Lawrence Corey · Fred Hutchinson Cancer Center$6,355,049
- Jane Ryan · Biota Scientific Management$5,628,310
- Christopher C. Whalen · Case Western Reserve University$5,165,940
- David B Clifford · Washington University$4,876,099
- William Robert Jacobs · Albert Einstein College Of Medicine$3,994,132
Research focus
Microorganism Disease ChemotherapyPatient Oriented ResearchHiv InfectionsHuman SubjectHuman Therapy EvaluationAntiviral AgentsLamivudineClinical ResearchZidovudineDrug Screening /EvaluationStavudineEfavirenzClinical Trial Phase IiiCombination Chemotherapy2'3'DideoxynucleosideAntiaids AgentReverse Transcriptase InhibitorsResearch PersonnelResourcesRitonavirSourceToxic EffectUnited States National Institutes Of HealthVirus Load
Grant awards (8)
A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINAVIR/RITONAVIR PLUS EF$7,746
M01 · FY2007 · RR · contact PI
A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINAVIR/RITONAVIR PLUS EF$46,886
M01 · FY2006 · RR · contact PI
PHASE III, RANDOMIZED, DOUBLE-BLIND COMPARISON OF THREE PROTEASE INHIBITOR-SP$31,257
M01 · FY2006 · RR · contact PI
PHASE III, RANDOMIZED, DOUBLE-BLIND COMPARISON OF THREE PROTEASE INHIBITOR-SP$78,342
M01 · FY2005 · RR
A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINAVIR/RITONAVIR PLUS EF$48,058
M01 · FY2005 · RR
Phase III, Randomized, Double-Blind Comparison of Three Protease Inhibitor-Sp...$81,525
M01 · FY2004 · RR
PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINA$35,206
M01 · FY2004 · RR
Role of Temporary Cessation of Antiretroviral Treatment$16,059
M01 · FY2004 · RR